Turning Point Therapeutics, Inc.
(NASDAQ : TPTX)

( )
TPTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. -1.96%76.550.7%$1026.24m
JNJJohnson & Johnson -3.36%134.440.7%$1017.35m
PFEPfizer Inc. -2.17%33.360.9%$980.19m
ABBVAbbVie, Inc. 0.05%85.462.3%$922.78m
BMYBristol-Myers Squibb Co. -0.79%59.111.0%$766.80m
LLYEli Lilly & Co. -2.14%126.431.1%$487.62m
NVSNovartis AG -2.45%83.910.2%$216.97m
GSKGlaxoSmithKline Plc -2.62%40.500.2%$178.79m
AZNAstraZeneca Plc -2.82%43.801.2%$152.17m
BHCBausch Health Cos., Inc. -1.73%22.130.0%$101.39m
SNYSanofi -3.97%46.250.2%$95.78m
RETAReata Pharmaceuticals, Inc. 3.22%194.753.4%$91.23m
NVONovo Nordisk A/S -2.27%58.140.1%$81.23m
VXRTVaxart, Inc. 16.19%2.870.0%$54.27m
GNPXGenprex, Inc. -12.29%4.110.0%$52.47m

Company Profile

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. It focuses on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.